- Book学术

发布求助

文献互助智能选刊最新文献

IF 3.3 3区心理学 Q1 BEHAVIORAL SCIENCES

Pharmacology Biochemistry and Behavior Pub Date : 2024-09-14 DOI:10.1016/j.pbb.2024.173878

引用次数: 0

摘要

焦虑症的特征是强烈的担忧和恐惧感，这会严重影响日常生活。目前的治疗方法主要包括选择性血清素再摄取抑制剂、苯二氮卓类药物、非苯二氮卓类抗焦虑药、加巴喷丁类药物和β-受体阻滞剂。神经肽在调节复杂行为（如精神病理学和焦虑相关反应）方面发挥着重要作用。神经肽在增进我们对焦虑症患者的了解和帮助他们的能力方面大有可为。本综述重点探讨神经肽在焦虑症治疗中不断扩大的作用，尤其是研究 P 物质、神经肽 Y、促肾上腺皮质激素释放激素、精氨酸加压素、垂体腺苷酸环化酶激活多肽和胆囊收缩素的影响。此外，本文还讨论了神经肽对焦虑相关反应的影响及其作为治疗靶点的潜力，这些神经肽正得到越来越多的认可。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anxiety and the brain: Neuropeptides as emerging factors

Anxiety disorders are characterized by intense feelings of worry and fear, which can significantly interfere with daily functioning. Current treatment options primarily include selective serotonin reuptake inhibitors, benzodiazepines, non-benzodiazepine anxiolytics, gabapentinoids, and beta-blockers. Neuropeptides have shown an important role in the regulation of complex behaviours, such as psychopathology and anxiety-related reactions. Neuropeptides have a great deal of promise to advance our understanding of and ability to help people with anxiety disorders. This review focuses on the expanding role of neuropeptides in anxiety management, particularly examining the impact of substance P, neuropeptide Y, corticotropin-releasing hormone, arginine-vasopressin, pituitary adenylate cyclase-activating polypeptide, and cholecystokinin. Furthermore, the paper discusses the neuropeptides that are becoming more and more recognized for their impact on anxiety-related reactions and their potential as therapeutic targets.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacology Biochemistry and Behavior 医学-行为科学

CiteScore

6.40

自引率

2.80%

发文量

122

审稿时长

38 days

期刊介绍： Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.